Causal relevance of circulating adiponectin with cancer: a meta-analysis implementing Mendelian randomization

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 585-594

  Pei, Yuan ^a   Xu, Yue ^a   Niu, Wenquan ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adiponectin; Cancer; Mendelian randomization; Meta analysis; Polymorphism

Indexed keywords

ADIPONECTIN;

ALLELE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CLINICAL ASSESSMENT; COLON CANCER; COLORECTAL CANCER; DISEASE ASSOCIATION; DNA POLYMORPHISM; EMBASE; ESOPHAGUS CANCER; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER CANCER; LUNG CANCER; MEDLINE; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS; NEOPLASM; OBESITY; PANCREAS CANCER; PATIENT RISK; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; STOMACH CANCER; SYSTEMATIC REVIEW; COLORECTAL TUMOR; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADIPONECTIN; ALLELES; COLORECTAL NEOPLASMS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBMED;

EID: 84925464934     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2654-x     Document Type: Article

References (50)

1. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33:547–94.
2. Hebbard L, Ranscht B. Multifaceted roles of adiponectin in cancer. Best Pract Res Clin Endocrinol Metab. 2014;28:59–69.
3. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33:30–42.
4. Al-Harithy RN, Al-Zahrani MH. The adiponectin gene, ADIPOQ, and genetic susceptibility to colon cancer. Oncol Lett. 2012;3:176–80.
5. Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA, et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 2012;8:e1002607.
6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
8. Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.
9. Doecke JD, Zhao ZZ, Stark MS, Green AC, Hayward NK, Montgomery GW, et al. Single nucleotide polymorphisms in obesity-related genes and the risk of esophageal cancers. Cancer Epidemiol Biomarkers Prev. 2008;17:1007–12.
10. Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, et al. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res. 2008;68:3178–84.
11. Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA. 2008;300:1523–31.
12. Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, et al. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J Gastroenterol Hepatol. 2008;23:914–21.
13. Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, et al. Adipokine genes and prostate cancer risk. Int J Cancer. 2009;124:869–76.
14. Pechlivanis S, Bermejo JL, Pardini B, Naccarati A, Vodickova L, Novotny J, et al. Genetic variation in adipokine genes and risk of colorectal cancer. Euro J Endocrinol. 2009;160:933–40.
15. Teras LR, Goodman M, Patel AV, Bouzyk M, Tang W, Diver WR, et al. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18:2553–7.
16. Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control. 2009;20:1739–51.
17. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate. 2009;69:874–85.
18. Beebe-Dimmer JL, Zuhlke KA, Ray AM, Lange EM, Cooney KA. Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. Prostate Cancer Prostatic Dis. 2010;13:362–8.
19. Partida-Perez M, de la Ayala-Madrigal LM, Peregrina-Sandoval J, Macias-Gomez N, Moreno-Ortiz J, Leal-Ugarte E, et al. Association of LEP and ADIPOQ common variants with colorectal cancer in Mexican patients. Cancer Biomark. 2010;7:117–21.
20. Al Khaldi RM, Al Mulla F, Al Awadhi S, Kapila K, Mojiminiyi OA. Associations of single nucleotide polymorphisms in the adiponectin gene with adiponectin levels and cardio-metabolic risk factors in patients with cancer. Dis Markers. 2011;30:197–212.
21. Cui E, Deng A, Wang X, Wang B, Mao W, Feng X, et al. The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer. Biochem Cell Biol. 2011;89:308–13.
22. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, et al. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2618–27.
23. Gornick MC, Rennert G, Moreno V, Gruber SB. Adiponectin gene and risk of colorectal cancer. Br J Cancer. 2011;105:562–4.
24. He B, Pan Y, Zhang Y, Bao Q, Chen L, Nie Z, et al. Effects of genetic variations in the adiponectin pathway genes on the risk of colorectal cancer in the Chinese population. BMC Med Genet. 2011;12:94.
25. Kaklamani V, Yi N, Zhang K, Sadim M, Offit K, Oddoux C, et al. Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metab Clin Exp. 2011;60:1234–43.
26. Tang H, Dong X, Hassan M, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:779–92.
27. Keku TO, Vidal A, Oliver S, Hoyo C, Hall IJ, Omofoye O, et al. Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites. Cancer Causes Control. 2012;23:1127–38.
28. Chornokur G, Amankwah EK, Davis SN, Phelan CM, Park JY, Pow-Sang J, et al. Variation in HNF1B and obesity may influence prostate cancer risk in African American men: a pilot study. Prostate Cancer. 2013;2013:384594.
29. Hu X, Yuan P, Yan J, Feng F, Li X, Liu W, et al. Gene polymorphisms of +45 T>G, −866 G>A, and Ala54Thr on the risk of colorectal cancer: a matched case-control study. PLoS One. 2013;8:e67275.
30. Kaklamani VG, Hoffmann TJ, Thornton TA, Hayes G, Chlebowski R, Van Horn L, et al. Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women’s Health Initiative. Breast Cancer Res Treat. 2013;139:461–8.
31. Ye L, Zhang ZY, Du WD, Schneider ME, Qiu Y, Zhou Y, et al. Genetic analysis of ADIPOQ variants and gastric cancer risk: a hospital-based case-control study in china. Med Oncol. 2013;30:658.
32. Cai X, Gan Y, Fan Y, Hu J, Jin Y, Chen F, et al. The adiponectin gene single-nucleotide polymorphism rs1501299 is associated with hepatocellular carcinoma risk. Clin Translational Oncol. 2014;16:166–72.
33. Llanos AA, Brasky TM, Mathew J, Makambi KH, Marian C, Dumitrescu RG, Freudenheim JL, Shields PG. Genetic variation in adipokine genes and associations with adiponectin and leptin concentrations in plasma and breast tissues. Cancer Epidemiol Biomarkers Prev. 2014;23(8):1559–68. doi:10.1158/1055-9965.
34. Li Q, Ma Y, Sang W, Cui W, Li X, Liu X, et al. Five common haplotype-tagging variants of adiponectin (ADIPOQ) and cancer susceptibility: a meta-analysis. Genet Test Mol Biomarkers. 2014;18:417–24.
35. Zhou W, Liu Y, Zhong DW. Adiponectin (ADIPOQ) rs2241766 G/T polymorphism is associated with risk of cancer: evidence from a meta-analysis. Tumour Biol. 2013;34:493–504.
36. Ye C, Wang J, Tan S, Zhang J, Li M, Sun P. Meta-analysis of adiponectin polymorphisms and colorectal cancer risk. Int J Med Sci. 2013;10:1113–20.
37. Yang Y, Zhang F, Ding R, Skrip L, Wang Y, Lei H, et al. ADIPOQ gene polymorphisms and cancer risk: a meta-analysis. Cytokine. 2013;61:565–71.
38. Fan HJ, Wen ZF, Xu BL, Wu JJ, Jia YX, Gao M, et al. Three adiponectin rs1501299G/T, rs822395A/C, and rs822396A/G polymorphisms and risk of cancer development: a meta-analysis. Tumour Biol. 2013;34:769–78.
39. Ye J, Jia J, Dong S, Zhang C, Yu S, Li L, et al. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014;23:158–65.
40. Macis D, Guerrieri-Gonzaga A, Gandini S. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(4):1226–36. doi:10.1093/ije/dyu088.
41. Liu LY, Wang M, Ma ZB, Yu LX, Zhang Q, Gao DZ, et al. The role of adiponectin in breast cancer: a meta-analysis. PLoS One. 2013;8:e73183.
42. An W, Bai Y, Deng SX, Gao J, Ben QW, Cai QC, et al. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev. 2012;21:126–33.
43. Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis. 2011;12:234–44.
44. Vanderweele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P. Methodological challenges in Mendelian randomization. Epidemiology. 2014;25:427–35.
45. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology. 2005;65:1168–72.
46. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11:466–72.
47. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565–74.
48. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237:109–14.
49. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003;88:993–7.
50. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet. 2001;2:91–9.